EUVIMEDEUVIMED entdecken
Open Access

CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target

Yang Yu iD, Yanling Zhao iD, Zhongcheng Shi iD, Larry L Wang iD, Feng Cheng iD, Amber Cecil iD, Nimesh Rudra iD, Jong Min Choi iD, Kan Li iD, Daniel Silverman iD, Dan Qi iD, Anil Prakash iD und 16 weitere

Journal of Experimental Medicine · 2026

DOI: 10.1084/jem.20252078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Yang Yu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital , Washington, DC, USA. Hauptthemen laut MEDLINE: Neuroblastoma. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Dan L. Duncan Cancer Center, NCI NIH HHS, Alex's Lemonade Stand Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase–like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a nonfunctional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaHumansAnimalsCell ProliferationCell Line, TumorMiceGene Expression Regulation, NeoplasticN-Myc Proto-Oncogene ProteinSignal Transduction

Substanzen

N-Myc Proto-Oncogene Protein

Autor:innen und Institutionen

  • Center for Cancer and Immunology Research, Children's National Research Institute, Children's National Hospital , Washington, DC, USA.
  • Department of Pediatrics, Texas Children's Hospital, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
  • Advanced Technology Cores, Baylor College of Medicine , Houston, TX, USA.
  • Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ, USA.

ORCID-Profile: Yang Yu, Yanling Zhao, Zhongcheng Shi, Larry L Wang, Feng Cheng, Amber Cecil, Nimesh Rudra, Jong Min Choi, Kan Li, Daniel Silverman, Dan Qi, Anil Prakash, Zhixing Wu, Jun Wang, Shenglin Mei, Anqing Zhang, Keita Ichii, Hanh-Xuan Nguyen, Brian R Rood, Jeffrey S Dome, Muller Fabbri, Joanna S Yi, Erxi Wu, Dai Lu, Sung Yun Jung, Saurabh Agarwal, Chunchao Zhang, Jianhua Yang

Förderung

  • Dan L. Duncan Cancer Center
  • NCI NIH HHS
  • Alex's Lemonade Stand Foundation
  • St. Baldrick's Scholar
  • NINDS NIH HHS
  • NIH HHS
  • Hyundai Hope on Wheels
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Yu, Y., Zhao, Y., Shi, Z., Wang, L. L., Cheng, F., Cecil, A., Rudra, N., Choi, J. M., Li, K., Silverman, D., Qi, D., Prakash, A., Wu, Z., Wang, J., Mei, S., Zhang, A., Ichii, K., Nguyen, H. X., Rood, B. R., …, & Yang, J. (2026). CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252078

Vancouver

Yu Y, Zhao Y, Shi Z, Wang LL, Cheng F, Cecil A, et al. CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20252078

BibTeX
@article{Yu2026,
  author = {Yu, Yang and Zhao, Yanling and Shi, Zhongcheng and Wang, Larry L and Cheng, Feng and Cecil, Amber and Rudra, Nimesh and Choi, Jong Min and Li, Kan and Silverman, Daniel and Qi, Dan and Prakash, Anil and Wu, Zhixing and Wang, Jun and Mei, Shenglin and Zhang, Anqing and Ichii, Keita and Nguyen, Hanh-Xuan and Rood, Brian R and Dome, Jeffrey S and Fabbri, Muller and Yi, Joanna S and Wu, Erxi and Lu, Dai and Jung, Sung Yun and Agarwal, Saurabh and Zhang, Chunchao and Yang, Jianhua},
  title = {CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target},
  journal = {Journal of Experimental Medicine},
  year = {2026},
  doi = {10.1084/jem.20252078}
}
Kostenlos starten →